Lymphoma clinical trials

The registry lists 3,018 studies for Lymphoma across more than 10 countries. 434 are recruiting or about to start. 1,042 of them are mainly about Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 21 narrower conditions too, such as Lymphoma, Non-Hodgkin: 8,676 studies, 1,874 open.

ClinicalTrials.gov finds 11,351 studies for Lymphoma. How that becomes 3,018 here

This page counts the studies the registry files under Lymphoma, and those it files under no condition that list Lymphomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

11,351Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−5,655Filed under a narrower condition, counted on its own pageLymphoma, Non-Hodgkin 1,556 · Lymphoma, Follicular 981 · Lymphoma, Large B-Cell, Diffuse 749 · Lymphoma, B-Cell 404 · Hodgkin Disease 349 · Lymphoma, Mantle-Cell 268 · 13 more
−874List Lymphoma as a condition, but the registry did not file them under itMost often written as “Small Lymphocytic Lymphoma” (114), “Primary Central Nervous System Lymphoma” (55), and “Lymphoblastic Lymphoma” (40). The registry filed 246 of them under no condition at all, and the others under other conditions only, most often Leukemia, Lymphocytic, Chronic, B-Cell (219) and Precursor Cell Lymphoblastic Leukemia-Lymphoma (117).
−1,804Match it another way354 name it in the title, 62 in a keyword, and 1,388 by a synonym or other text the search reads.
3,018The count on this page

Get an email when these change. Save the Lymphoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,620
Terminated: 375
Recruiting: 347
Status unknown: 270
Active, not recruiting: 169
Withdrawn: 129

Phase

Phase 2: 1,276
Phase 1: 1,069
Phase 3: 225
Early Phase 1: 41
Phase 4: 35

Where

United States: 1,909
China: 275
France: 237
Canada: 196
United Kingdom: 194
Italy: 158

Who runs them

National Cancer Institute (NCI) (170) · M.D. Anderson Cancer Center (153) · Memorial Sloan Kettering Cancer Center (99) · Alliance for Clinical Trials in Oncology (45) · Children's Oncology Group (35) · SWOG Cancer Research Network (34) · Fred Hutchinson Cancer Center (32) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (32)

What is being tested here

Drugs under test in Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Rituximab	11	28	253
Venetoclax	11	0	16
Cyclophosphamide	10	13	179
Fludarabine	8	4	106
Lenalidomide	6	4	47
Glofitamab	5	1	8
Epcoritamab	5	2	8
Immunoglobulins, Intravenous	5	4	5
Immunoglobulin G	5	4	5
Doxorubicin	4	9	56

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 18 open · Antimetabolites 16 open · Immune checkpoint inhibitors 16 open · Alkylating agents 14 open · Corticosteroids 7 open

Coming up

37phase 3 studies under way

175studies finish main data collection within a year14 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Post-Op Pain Control for Prophylactic Intramedullary Nailing. · Phase 3 · St. Louis University
Jan 2027A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL · Phase 3 · Xia Yi
Feb 2027A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) · Phase 3 · Acerta Pharma BV
Feb 2027Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy · Phase 3 · Peking University First Hospital
Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 3 · Monash University
Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 3 · Monash University
Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 3 · Monash University
Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) · Phase 3 · Monash University
Apr 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension · Phase 3 · Monash University
May 2027Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial · Phase 3 · University of Rochester

Who these studies take

Of the 347 Lymphoma studies recruiting now, 227 (65%) set no upper age limit and 79 (23%) stop at 75 or younger. 78 (22%) take children under 18. 4 (1%) are for women only and 0 (0%) for men only; 20 (6%) take healthy volunteers.

Recruiting studies that take each age, of 347
Age	Women	Men
10	55 (16%)	54 (16%)
18	318 (92%)	315 (91%)
30	317 (91%)	314 (90%)
40	314 (90%)	311 (90%)
50	309 (89%)	308 (89%)
65	313 (90%)	312 (90%)
75	291 (84%)	290 (84%)
85	256 (74%)	255 (73%)

Across all 3,018 studies, recruiting or not: 29% stop at 75 or younger and 17% at 65; 26% take children; 1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma studies take

Of 293 phase 2 interventional studies under Lymphoma, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	53 mo34–77 · 281 studies	44 mo24–61 · 143 studies	64 mo39–88 · 138 studies
Phase 1/2	74 mo48–111 · 143 studies	65 mo41–87 · 66 studies	79 mo49–133 · 77 studies
Phase 2	61 mo36–105 · 293 studies	36 mo26–65 · 56 studies	67 mo42–114 · 237 studies
Phase 3	67 mo52–106 · 62 studies	57 mo52–69 · 29 studies	89 mo59–116 · 33 studies
Interventional, no phase	43 mo23–87 · 170 studies	—	44 mo25–87 · 161 studies
Observational	82 mo39–269 · 159 studies	—	90 mo41–269 · 140 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Show 3 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,018. Browse all 3,018 → or search them.